Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773189 | 0.83 | GRM5 (0.47) | GRM5KDM4ELMNAMAPK1L3MBTL1 | |
| SCHEMBL23925904 | 0.78 | HSD17B14 (0.42) | ARKMT2AMEN1CYP1A1CYP1B1 | |
| SCHEMBL5478842 | 0.77 | AR (0.53) | ARKDM4ELMNAMAPK1SLC6A4 | |
| SCHEMBL21610255 | 0.76 | BRAF (0.45) | HTR2ASLC6A4KCNH2KDR | |
| SCHEMBL17609079 | 0.76 | GRM5 (0.49) | GRM5KDM4EL3MBTL1SLC22A12SLC6A4 | |
| SCHEMBL11296944 | 0.74 | GRM5 (0.51) | GRM5KDM4ELMNA | |
| SCHEMBL24690169 | 0.74 | GRM5 (0.51) | GRM5KDM4ELMNAMAPK1L3MBTL1 | |
| SCHEMBL30020111 | 0.74 | GRM5 (0.51) | GRM5KDM4ELMNAMAPK1L3MBTL1 | |
| SCHEMBL18049170 | 0.73 | GRM5 (0.51) | GRM5KDM4ELMNAMAPK1L3MBTL1 | |
| SCHEMBL23504272 | 0.73 | GRM5 (0.65) | GRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | GRM5 2973/4885AR 1419/4885KDM4E 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.